1. Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions
   Makito Miyake et al, 2013, Journal of Hematology & Oncology CrossRef
2. Induction of erythropoietin increases the cell proliferation rate in a hypoxia-inducible factor-1-dependent and -independent manner in renal cell carcinoma cell lines
   YUTAKA FUJISUE et al, 2013, Oncology Letters CrossRef
3. p.N78S and p.R161Q germline mutations of the VHL gene are present in von Hippel-Lindau syndrome in two pedigrees
   XIAO-PING QI et al, 2013, Molecular Medicine Reports CrossRef
4. Systemic VHL gene functions and the VHL disease
   Hannah L. Bader et al, 2012, FEBS Letters CrossRef
5. The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness
   Bin Bao et al, 2012, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
6. Inactivation of von Hippel-Lindau increases ovarian cancer cell aggressiveness through the HIF1α/miR-210/VMP1 signaling pathway
   TING LIU et al, 2014, International Journal of Molecular Medicine CrossRef
7. Successful treatment of erythropoietin-producing advanced renal cell carcinoma after targeted therapy using sunitinib: Case report and review of the literature
   KOSUKE UEDA et al, 2013, Molecular and Clinical Oncology CrossRef
8. Functional significance of erythropoietin in renal cell carcinoma
   Christudas Morais et al, 2013, BMC Cancer CrossRef
9. Peking University - Juntendo University Joint Symposium on Cancer Research and Treatment
   KAN GONG et al, 2017, Juntendo Medical Journal CrossRef